

Evandro de Azambuja

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2155806/publications.pdf>

Version: 2024-02-01

210
papers

17,878
citations

22099

59
h-index

14156

128
g-index

213
all docs

213
docs citations

213
times ranked

20848
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 467-470.	3.0	13
2	Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 457-462.	1.1	4
3	Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline <i>BRCA</i> pathogenic variants having a pregnancy after breast cancer. <i>Cancer Research</i> , 2022, 82, PD5-06-PD5-06.	0.4	0
4	Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 567-591.	1.9	29
5	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. <i>European Journal of Cancer</i> , 2022, 166, 219-228.	1.3	12
6	Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. <i>Clinical Breast Cancer</i> , 2022, 22, 308-318.	1.1	2
7	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1117-1126.	3.0	3
8	Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis. <i>ESMO Open</i> , 2022, 7, 100501.	2.0	12
9	Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. <i>Oncologist</i> , 2022, 27, 722-731.	1.9	6
10	Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. <i>European Journal of Cancer</i> , 2021, 144, 351-359.	1.3	2
11	CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13535.	1.7	14
12	The Exciting New Field of HER2-Low Breast Cancer Treatment. <i>Cancers</i> , 2021, 13, 1015.	1.7	83
13	Emerging Therapeutics for Patients with Triple-Negative Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 57.	1.8	30
14	OncoAlert Round Table Discussions: The Global COVID-19 Experience. <i>JCO Global Oncology</i> , 2021, 7, 455-463.	0.8	6
15	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 67.	2.3	8
16	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021, 39, 1448-1457.	0.8	171
17	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). <i>European Journal of Cancer</i> , 2021, 148, 287-296.	1.3	11
18	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 76-91.	1.3	33

#	ARTICLE	IF	CITATIONS
19	Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2394-2405.	13.9	764
20	Emerging issues related to COVID-19 vaccination in patients with cancer. <i>Oncology and Therapy</i> , 2021, 1-11.	1.0	15
21	Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. <i>Breast</i> , 2021, 57, 86-94.	0.9	6
22	HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. <i>Cancers</i> , 2021, 13, 2824.	1.7	117
23	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 945-962.	1.4	26
24	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
25	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 3293-3305.	0.8	70
26	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5607-5618.	3.2	5
27	Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103365.	2.0	48
28	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. <i>Clinical Cancer Research</i> , 2021, 27, 6307-6313.	3.2	8
29	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2021, 59, 183-192.	0.9	10
30	Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean. <i>Lancet Oncology</i> , The, 2021, 22, e488-e500.	5.1	17
31	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in <i>BRCA1/2</i> with a pregnancy after prior history of breast cancer. <i>ESMO Open</i> , 2021, 6, 100300.	2.0	9
32	Targeted therapy for breast cancer in older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 380-388.	0.5	9
33	A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 161-171.	1.1	39
34	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , 2020, 147, 160-169.	2.3	12
35	Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2020, 126, 65-73.	1.3	58
36	Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. <i>ESMO Open</i> , 2020, 5, e000947.	2.0	63

#	ARTICLE	IF	CITATIONS
37	Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial. <i>ESMO Open</i> , 2020, 5, e000979.	2.0	2
38	CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?. <i>ESMO Open</i> , 2020, 5, e001132.	2.0	5
39	Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?. <i>ESMO Open</i> , 2020, 5, e001112.	2.0	30
40	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. <i>ESMO Open</i> , 2020, 5, e000793.	2.0	113
41	Are We RESPECTing Older Patients With Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2020, 38, 3727-3730.	0.8	0
42	Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. <i>ESMO Open</i> , 2020, 5, e000842.	2.0	16
43	Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. <i>European Journal of Cancer</i> , 2020, 139, 43-50.	1.3	267
44	Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer. <i>ESMO Open</i> , 2020, 5, e000688.	2.0	0
45	Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 563-573.	1.1	2
46	Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. <i>British Journal of Cancer</i> , 2020, 122, 1453-1460.	2.9	22
47	The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). <i>Acta Oncol³gica</i> , 2020, 59, 723-725.	0.8	7
48	Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 262-273.e7.	1.1	14
49	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1386.	1.8	33
50	Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 149, 102940.	2.0	5
51	Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. <i>ESMO Open</i> , 2020, 5, e000659.	2.0	6
52	HER2-positive advanced breast cancer treatment in 2020. <i>Cancer Treatment Reviews</i> , 2020, 88, 102033.	3.4	70
53	Malignant bowel obstruction: effectiveness and safety of systemic chemotherapy. <i>BMJ Supportive and Palliative Care</i> , 2020, , bmjspcare-2020-002656.	0.8	2
54	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2019, 111, 86-94.	3.0	73

#	ARTICLE	IF	CITATIONS
55	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1226-1238.	5.1	76
56	Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 169-177.	1.3	51
57	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. <i>European Journal of Cancer</i> , 2019, 118, 1-9.	1.3	11
58	PERSEPHONE - implications for clinical practice in 2019. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 663-664.	12.5	1
59	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 103-114.	1.1	34
60	Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 607-615.	1.1	10
61	Denosumab in early-stage breast cancer. <i>Lancet Oncology</i> , The, 2019, 20, e234-e235.	5.1	2
62	ER+/HER2+ breast cancer: are we really de-escalating?. <i>Annals of Oncology</i> , 2019, 30, 875-877.	0.6	4
63	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591982771.	1.4	38
64	Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3887-3895.	3.2	42
65	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3581-3588.	3.2	73
66	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 105-114.	0.8	72
67	Pertuzumab in HER2-positive early breast cancer: current use and perspectives. <i>Future Oncology</i> , 2019, 15, 1823-1843.	1.1	14
68	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. <i>Anticancer Research</i> , 2019, 39, 797-802.	0.5	0
69	How I treat metastatic triple-negative breast cancer. <i>ESMO Open</i> , 2019, 4, e000504.	2.0	59
70	Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2019, 24, e1034-e1043.	1.9	13
71	Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. <i>Annals of Oncology</i> , 2019, 30, x27-x42.	0.6	63
72	Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 43-51.	1.1	5

#	ARTICLE	IF	CITATIONS
73	Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 27-37.	1.1	40
74	Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 1-07) trials. <i>Journal of Clinical Oncology</i> , 2019, 37, 170-177.	10.0	157
75	Oncofertility counselling in premenopausal women with HER2-positive breast cancer. <i>Oncotarget</i> , 2019, 10, 926-929.	0.8	6
76	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. <i>International Journal of Oncology</i> , 2018, 52, 424-432.	1.4	9
77	Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Breast</i> , 2018, 39, 14-18.	0.9	14
78	Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?. <i>ESMO Open</i> , 2018, 3, e000350.	2.0	8
79	Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 135-144.	2.0	14
80	Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 316-324.	0.4	50
81	Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?. <i>ESMO Open</i> , 2018, 3, e000324.	2.0	10
82	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). <i>Breast Cancer Research and Treatment</i> , 2018, 168, 631-638.	1.1	49
83	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018, 24, 3079-3086.	3.2	15
84	Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. <i>Journal of the National Cancer Institute</i> , 2018, 110, 426-429.	3.0	143
85	Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 62, 123-132.	3.4	16
86	Risk factors for the development of brain metastases in patients with HER2-positive breast cancer. <i>ESMO Open</i> , 2018, 3, e000440.	2.0	27
87	In Reply to Belkacemi and Tsoutsou. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 467-468.	0.4	0
88	CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2018, 3, e000368.	2.0	35
89	Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 629-649.	1.1	31
90	Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2018, 3, e000361.	2.0	49

#	ARTICLE	IF	CITATIONS
91	Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2018, 8, 156.	1.3	26
92	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, e181564.	3.4	13
93	Meta-analysis of the cardiac events in the adjuvant trastuzumab trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10066-10066.	0.8	2
94	An individual patient level data pooled analysis of T-DM1 cardiac safety in HER2-positive (HER2+) metastatic breast cancer (MBC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10068-10068.	0.8	2
95	Choice of chemotherapy regimen for early HER2-positive breast cancer in elderly patients. <i>Chinese Clinical Oncology</i> , 2018, 7, 4-4.	0.4	2
96	Role of Troponins I and T and <i>N</i> -Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. <i>Journal of Clinical Oncology</i> , 2017, 35, 878-884.	0.8	113
97	11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. <i>Lancet, The</i> , 2017, 389, 1195-1205.	6.3	770
98	Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 4.	1.3	17
99	Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2017, 57, 8-15.	3.4	75
100	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	13
101	The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data. <i>Clinical Cancer Research</i> , 2017, 23, 2702-2712.	3.2	82
102	Recurrence dynamics of breast cancer according to baseline body mass index. <i>European Journal of Cancer</i> , 2017, 87, 10-20.	1.3	35
103	HER2-positive breast cancer is lost in translation: time for patient-centered research. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 669-681.	12.5	59
104	Male breast cancer: finding the way in this uncommon path. <i>ESMO Open</i> , 2017, 2, e000169.	2.0	1
105	Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1205-1215.	1.5	1
106	Breast cancer treatment-induced cardiotoxicity. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1021-1038.	1.0	58
107	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 122-131.	13.9	1,033
108	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42.	2.9	920

#	ARTICLE	IF	CITATIONS
109	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. <i>JAMA Oncology</i> , 2017, 3, 227.	3.4	118
110	Adjuvant trastuzumab: a 10-year overview of its benefit. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 61-74.	1.1	40
111	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3363-3372.	1.0	11
112	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1421-1429.	0.8	116
113	Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 512-512.	0.8	8
114	Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA. <i>PLoS ONE</i> , 2017, 12, e0172351.	1.1	10
115	Phosphoethanolamine and the danger of unproven drugs. <i>Ecancermedalscience</i> , 2016, 10, 681.	0.6	3
116	Threat posed by unproven drugs in medical oncology. <i>ESMO Open</i> , 2016, 1, e000064.	2.0	1
117	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016, 1, e000107.	2.0	11
118	I-SPY 2: optimising cancer drug development in the 21st century. <i>ESMO Open</i> , 2016, 1, e000113.	2.0	11
119	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. <i>JAMA Oncology</i> , 2016, 2, 1040.	3.4	73
120	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw037.	3.0	24
121	Twenty years of anti-HER2 therapy-associated cardiotoxicity. <i>ESMO Open</i> , 2016, 1, e000073.	2.0	76
122	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. <i>British Journal of Cancer</i> , 2016, 115, 1471-1478.	2.9	45
123	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 127-132.	1.1	7
124	Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries. <i>Maturitas</i> , 2016, 84, 81-88.	1.0	16
125	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1034-1042.	0.8	315
126	Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0154009.	1.1	27

#	ARTICLE	IF	CITATIONS
127	Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. <i>Oncotarget</i> , 2016, 7, 13209-13220.	0.8	5
128	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. <i>Clinical Cancer Research</i> , 2015, 21, 569-576.	3.2	71
129	<i>PIK3CA</i> Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1334-1339.	0.8	201
130	Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors \leq 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 2600-2608.	0.8	91
131	Final 10-year results of the Breast International Group 98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 1481-1489.	1.3	32
132	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. <i>JAMA Oncology</i> , 2015, 1, 448.	3.4	482
133	Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. <i>European Journal of Cancer</i> , 2015, 51, 2517-2524.	1.3	40
134	An update on PARP inhibitors moving to the adjuvant setting. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 27-41.	12.5	316
135	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 425.	0.6	19
136	Reply to C. Fontanella et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3459-3459.	0.8	1
137	Cardiotoxicity of systemic agents used in breast cancer. <i>Breast</i> , 2014, 23, 317-328.	0.9	49
138	An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case. <i>European Journal of Cancer</i> , 2014, 50, 3089-3097.	1.3	13
139	Menopausal hormone therapy use in 17 European countries during the last decade. <i>Maturitas</i> , 2014, 79, 287-291.	1.0	55
140	Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. <i>Journal of Clinical Oncology</i> , 2014, 32, 2794-2803.	0.8	298
141	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. <i>Lancet Oncology</i> , The, 2014, 15, 1137-1146.	5.1	382
142	Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. <i>Breast</i> , 2014, 23, 473-481.	0.9	11
143	Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). <i>Journal of Clinical Oncology</i> , 2014, 32, 2159-2165.	0.8	207
144	First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T+L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA4-LBA4.	0.8	32

#	ARTICLE	IF	CITATIONS
145	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. <i>Lancet</i> , The, 2013, 382, 1021-1028.	6.3	447
146	Planning cancer control in Latin America and the Caribbean. <i>Lancet Oncology</i> , The, 2013, 14, 391-436.	5.1	394
147	¹⁸ F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1862-1868.	2.8	132
148	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. <i>Journal of Clinical Oncology</i> , 2013, 31, 860-867.	0.8	1,342
149	Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 13-22.	1.1	114
150	Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies. <i>Breast</i> , 2013, 22, S152-S155.	0.9	84
151	Supportive care after curative treatment for breast cancer (survivorship care): Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. <i>Breast</i> , 2013, 22, 606-615.	0.9	87
152	Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial. <i>Breast</i> , 2013, 22, 1060-1065.	0.9	33
153	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). <i>Lancet Oncology</i> , The, 2013, 14, 244-248.	5.1	172
154	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 935-946.	3.4	308
155	Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP). <i>Journal of Chemotherapy</i> , 2013, 25, 239-246.	0.7	5
156	Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1954-1960.	0.8	39
157	Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience. <i>Oncologist</i> , 2013, 18, 134-140.	1.9	29
158	Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 73-79.	0.8	215
159	Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4504-4511.	0.8	60
160	Clinical practice-changing trials: the HERA study paradigm. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1249-1256.	1.1	4
161	How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer. <i>Breast Care</i> , 2013, 8, 264-269.	0.8	2
162	Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer. <i>Onkologie</i> , 2012, 35, 476-478.	1.1	2

#	ARTICLE	IF	CITATIONS
163	Dual human epidermal growth factor receptor 2 blockade. <i>Current Opinion in Oncology</i> , 2012, 24, 612-622.	1.1	12
164	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2012, 379, 633-640.	6.3	1,165
165	Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer – Authors' reply. <i>Lancet, The</i> , 2012, 379, 2238.	6.3	0
166	Targeted therapies in breast cancer: are heart and vessels also being targeted?. <i>Breast Cancer Research</i> , 2012, 14, 209.	2.2	24
167	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. <i>Breast Cancer Research</i> , 2012, 14, R70.	2.2	52
168	Dissecting the Heterogeneity of Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1879-1887.	0.8	388
169	Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond. <i>Breast Cancer Management</i> , 2012, 1, 217-233.	0.2	2
170	Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. <i>Journal of Oncology</i> , 2012, 2012, 1-8.	0.6	79
171	Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). <i>Breast Cancer Research and Treatment</i> , 2012, 133, 387-391.	1.1	61
172	Improving quality of life after breast cancer: Dealing with symptoms. <i>Maturitas</i> , 2011, 70, 343-348.	1.0	105
173	Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?. <i>Lancet Oncology, The</i> , 2011, 12, 209-211.	5.1	22
174	HER2-overexpressing breast cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 547-558.	1.1	18
175	Beyond trastuzumab: New treatment options for HER2-positive breast cancer. <i>Breast</i> , 2011, 20, S20-S27.	0.9	53
176	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2011, 13, 1-10.	2.9	350
177	Multifactorial Approach to Predicting Resistance to Anthracyclines. <i>Journal of Clinical Oncology</i> , 2011, 29, 1578-1586.	0.8	169
178	Neoadjuvant Chemotherapy and Targeted Therapies: a Promising Strategy. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 116-119.	0.9	2
179	Motherhood after breast cancer: searching for la dolce vita. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 287-298.	1.1	41
180	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 147-151.	0.9	61

#	ARTICLE	IF	CITATIONS
181	The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 145-153.	1.1	137
182	Brain metastases in HER2-positive breast cancer: The evolving role of lapatinib. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 75, 110-121.	2.0	38
183	Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3422-3428.	0.8	228
184	Sequential or Concurrent Administration of Trastuzumab in Early Breast Cancer? Too Early to Judge. <i>Journal of Clinical Oncology</i> , 2010, 28, e353-e354.	0.8	6
185	HER-2 as a Target for Breast Cancer Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 1848-1852.	3.2	36
186	Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2009, 9, 148-162.	0.8	53
187	Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 720-725.	0.8	23
188	Disease-Free Survival According to Degree of <i>HER2</i> Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 2962-2969.	0.8	164
189	Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?. <i>Targeted Oncology</i> , 2009, 4, 77-88.	1.7	90
190	Are we HER-ting for innovation in neoadjuvant breast cancer trial design?. <i>Breast Cancer Research</i> , 2009, 11, 201.	2.2	9
191	Larotaxel: broadening the road with new taxanes. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1183-1189.	1.9	56
192	Novel therapeutics in breast cancer—Looking to the future. <i>Update on Cancer Therapeutics</i> , 2009, 3, 189-205.	0.9	7
193	Current perspectives of epothilones in breast cancer. <i>European Journal of Cancer</i> , 2008, 44, 341-352.	1.3	18
194	Jumping higher: is it still possible? The ALTTO trial challenge. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1883-1890.	1.1	43
195	Facts and controversies in the use of trastuzumab in the adjuvant setting. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 645-654.	4.3	18
196	HER-2 Positive Breast Cancer: What Else Beyond Trastuzumab-Based Therapy?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2008, 8, 488-496.	0.9	30
197	Achievements in Systemic Therapies in the Pergenomic Era in Metastatic Breast Cancer. <i>Oncologist</i> , 2007, 12, 253-270.	1.9	85
198	Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers. <i>Oncologist</i> , 2007, 12, 1443-1455.	1.9	297

#	ARTICLE	IF	CITATIONS
199	The 17q12-q21 amplicon: Her2 and topoisomerase-III± and their importance to the biology of solid tumours. <i>Cancer Treatment Reviews</i> , 2007, 33, 64-77.	3.4	69
200	Molecular targeted therapies in breast cancer: Where are we now?. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1375-1387.	1.2	32
201	Trastuzumab (Herceptin) for Early-Stage Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 239-256.	0.9	6
202	Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "œdo ut des" Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.0	76
203	Long-term survival in pituitary metastasis from breast cancer. <i>Breast</i> , 2006, 15, 445-446.	0.9	4
204	Molecular markers of head and neck squamous cell carcinoma: Promising signs in need of prospective evaluation. <i>Head and Neck</i> , 2006, 28, 256-269.	0.9	125
205	Molecular Profiling of a Tumor of Unknown Origin. <i>New England Journal of Medicine</i> , 2006, 355, 1071-1072.	13.9	42
206	End-of-Life Care: The Red Alert for Physicians. <i>Oncologist</i> , 2006, 11, 851-852.	1.9	1
207	Breast Cancer: Achievements in Adjuvant Systemic Therapies in the Pre-Genomic Era. <i>Oncologist</i> , 2006, 11, 111-125.	1.9	52
208	OPTIMOX1 in Advanced Colorectal Cancer: Lack of Evidence for a Stop-and-Go Strategy. <i>Journal of Clinical Oncology</i> , 2006, 24, 5176-5177.	0.8	4
209	Pulmonary epithelial permeability in patients treated with bleomycin containing chemotherapy detected by technetium-99m diethylene triamine penta-acetic acid aerosol (99mTc-DTPA) scintigraphy. <i>Annals of Nuclear Medicine</i> , 2005, 19, 131-135.	1.2	5
210	Shrinking the Tumor, Shrinking the Patient Sample Size: The Early Disclosure Dilemma. <i>Journal of Clinical Oncology</i> , 2005, 23, 6803-6804.	0.8	4